RAS-Targeted Drug Discovery Summit 2019
September 17 - 19, 2019 - Boston MA USHanson Wade
info@hansonwade.com
Phone:6174554188
Following the exciting clinical progression from Amgen and Mirati Therapeutics, at a time when there is a translational opportunity to finally “drug” RAS proteins with clinically meaningful success, the 1st RAS- Targeted Drug Discovery Summit has been established to unite large pharma, biotech and academic KOLs who are striving to capitalize on the therapeutic potential of targeting RAS. With RAS mutations prevalent in approximately 30% of all cancers diagnosed, the clinical, patient outcome and commercial opportunity are tremendous. As such, the RAS- Targeted Drug Discovery Summit will be dedicated to helping oncology drug discovery and development professionals understand the cutting edge dynamics and function of RAS biology, identify and validate druggable target sites and improve the preclinical predictability of patient-derived and disease-specific RAS models. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the 1st RAS- Targeted Drug Discovery Summit – the only industry and translational focused conference dedicated to advancing pioneering RAS biology and drug discovery into successful clinical candidates.